首页 > 市场调查报告书 > 製药

自体免疫疾病

全球僵直性脊椎炎市场研究报告 - 2023 年至 2030 年产业分析、规模、份额、成长、趋势与预测

市场调查报告书

商品编码

1377873

全球僵直性脊椎炎市场研究报告 - 2023 年至 2030 年产业分析、规模、份额、成长、趋势与预测

Global Ankylosing Spondylitis Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年09月01日 | 出版商:

Value Market Research | 英文 125 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计全球僵直性脊椎炎市场需求将从 2022 年的 52.9 亿美元增至 2030 年的近 108.5 亿美元，2023-2030 年研究期间CAGR为 9.4%。

僵直性脊椎炎 (AS) 是一种持续性自体免疫疾病，主要针对脊椎和荐髂关节，但也会影响其他关节和器官。它属于脊椎关节炎类别，是一组以关节和附着点发炎（韧带和肌腱附着在骨骼上的位置）为特征的疾病。

市场动态：

对僵直性脊椎炎认知的提高、诊断方法的改进以及治疗方案的进步，特别是生物疗法和疾病缓解药物，正在推动市场发展。全球人口老化导致更多人面临这种疾病的风险，进一步增加了对僵直性脊椎炎相关医疗保健服务的需求。基因研究和新兴市场正在扩大市场范围。监管支持、以患者为中心的护理和数位健康解决方案也正在推动僵直性脊椎炎市场向前发展。正在进行的研究和临床试验有望带来新的治疗方式和疗法，促进其管理的持续创新。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球僵直性脊椎炎市场的每个细分市场进行了包容性评估。僵直性脊椎炎产业的成长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲僵直性脊椎炎市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。僵直性脊椎炎市场的主要参与者包括艾伯维公司、安进公司、辉瑞公司、诺华公司、礼来公司、UCB公司。本节包括竞争格局的整体视图，其中包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 7 章：僵直性脊椎炎公司的竞争格局

僵直性脊椎炎市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 8 章：公司简介

公司股份分析
市场集中度
AbbVie, Inc.

公司简介
公司收入
产品
最近的发展

Amgen, Inc.

公司简介
公司收入
产品
最近的发展

Pfizer, Inc.

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Eli Lilly and Company

公司简介
公司收入
产品
最近的发展

UCB, Inc.

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112112244

The global demand for Ankylosing Spondylitis Market is presumed to reach the market size of nearly USD 10.85 BN by 2030 from USD 5.29 BN in 2022 with a CAGR of 9.4% under the study period 2023 - 2030.

Ankylosing spondylitis (AS) is a persistent autoimmune condition that predominantly targets the spine and sacroiliac joints, but it can also impact other joints and organs. It belongs to the category of spondyloarthritis, a cluster of disorders characterized by joint and enthesis inflammation (the locations where ligaments and tendons attach to bones).

MARKET DYNAMICS:

Increased awareness of ankylosing spondylitis, improved diagnostic methods, and advancements in treatment options, particularly biologic therapies and disease-modifying drugs, are driving the market. The aging global population contributes to a greater number of individuals at risk of this condition, further increasing demand for ankylosing spondylitis-related healthcare services. Genetic research and emerging markets are expanding the market's reach. Regulatory support, patient-centric care, and digital health solutions are also propelling the ankylosing spondylitis market forward. Ongoing research and clinical trials promise new treatment modalities and therapies, fostering continued innovation in its management.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of ankylosing spondylitis. The growth and trends of ankylosing spondylitis industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the ankylosing spondylitis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug

Cosentyx
Humira
Simponi
Remicade
Enbrel
Cimzia
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Ankylosing Spondylitis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Ankylosing Spondylitis market include AbbVie, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Eli Lilly and Company, UCB, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ANKYLOSING SPONDYLITIS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug
- 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANKYLOSING SPONDYLITIS MARKET ANALYSIS BY DRUG

5.1 Overview by Drug
5.2 Historical and Forecast Data
5.3 Analysis by Drug
5.4 Cosentyx Historic and Forecast Sales by Regions
5.5 Humira Historic and Forecast Sales by Regions
5.6 Simponi Historic and Forecast Sales by Regions
5.7 Remicade Historic and Forecast Sales by Regions
5.8 Enbrel Historic and Forecast Sales by Regions
5.9 Cimzia Historic and Forecast Sales by Regions
5.10. Others Historic and Forecast Sales by Regions

6 . GLOBAL ANKYLOSING SPONDYLITIS MARKET ANALYSIS BY GEOGRAPHY

6.1. Regional Outlook
6.2. Introduction
6.3. North America Sales Analysis
- 6.3.1. Overview, Historic and Forecast Data Sales Analysis
- 6.3.2. North America By Segment Sales Analysis
- 6.3.3. North America By Country Sales Analysis
- 6.3.4. United State Sales Analysis
- 6.3.5. Canada Sales Analysis
- 6.3.6. Mexico Sales Analysis
6.4. Europe Sales Analysis
- 6.4.1. Overview, Historic and Forecast Data Sales Analysis
- 6.4.2. Europe by Segment Sales Analysis
- 6.4.3. Europe by Country Sales Analysis
- 6.4.4. United Kingdom Sales Analysis
- 6.4.5. France Sales Analysis
- 6.4.6. Germany Sales Analysis
- 6.4.7. Italy Sales Analysis
- 6.4.8. Russia Sales Analysis
- 6.4.9. Rest Of Europe Sales Analysis
6.5. Asia Pacific Sales Analysis
- 6.5.1. Overview, Historic and Forecast Data Sales Analysis
- 6.5.2. Asia Pacific by Segment Sales Analysis
- 6.5.3. Asia Pacific by Country Sales Analysis
- 6.5.4. China Sales Analysis
- 6.5.5. India Sales Analysis
- 6.5.6. Japan Sales Analysis
- 6.5.7. South Korea Sales Analysis
- 6.5.8. Australia Sales Analysis
- 6.5.9. South East Asia Sales Analysis
- 6.5.10. Rest Of Asia Pacific Sales Analysis
6.6. Latin America Sales Analysis
- 6.6.1. Overview, Historic and Forecast Data Sales Analysis
- 6.6.2. Latin America by Segment Sales Analysis
- 6.6.3. Latin America by Country Sales Analysis
- 6.6.4. Brazil Sales Analysis
- 6.6.5. Argentina Sales Analysis
- 6.6.6. Peru Sales Analysis
- 6.6.7. Chile Sales Analysis
- 6.6.8. Rest of Latin America Sales Analysis
6.7. Middle East & Africa Sales Analysis
- 6.7.1. Overview, Historic and Forecast Data Sales Analysis
- 6.7.2. Middle East & Africa by Segment Sales Analysis
- 6.7.3. Middle East & Africa by Country Sales Analysis
- 6.7.4. Saudi Arabia Sales Analysis
- 6.7.5. UAE Sales Analysis
- 6.7.6. Israel Sales Analysis
- 6.7.7. South Africa Sales Analysis
- 6.7.8. Rest Of Middle East And Africa Sales Analysis

7 . COMPETITIVE LANDSCAPE OF THE ANKYLOSING SPONDYLITIS COMPANIES

7.1. Ankylosing Spondylitis Market Competition
7.2. Partnership/Collaboration/Agreement
7.3. Merger And Acquisitions
7.4. New Product Launch
7.5. Other Developments

8 . COMPANY PROFILES OF ANKYLOSING SPONDYLITIS INDUSTRY

8.1. Company Share Analysis
8.2. Market Concentration Rate
8.3. AbbVie, Inc.
- 8.3.1. Company Overview
- 8.3.2. Company Revenue
- 8.3.3. Products
- 8.3.4. Recent Developments
8.4. Amgen, Inc.
- 8.4.1. Company Overview
- 8.4.2. Company Revenue
- 8.4.3. Products
- 8.4.4. Recent Developments
8.5. Pfizer, Inc.
- 8.5.1. Company Overview
- 8.5.2. Company Revenue
- 8.5.3. Products
- 8.5.4. Recent Developments
8.6. Novartis AG
- 8.6.1. Company Overview
- 8.6.2. Company Revenue
- 8.6.3. Products
- 8.6.4. Recent Developments
8.7. Eli Lilly and Company
- 8.7.1. Company Overview
- 8.7.2. Company Revenue
- 8.7.3. Products
- 8.7.4. Recent Developments
8.8. UCB, Inc.
- 8.8.1. Company Overview
- 8.8.2. Company Revenue
- 8.8.3. Products
- 8.8.4. Recent Developments